Latest News & Features
Genetics
The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops. 9 April 2015
Americas
There are important differences between the EPO and the USPTO in the assessment of patentable subject matter in life sciences. Depending on the technology involved, patentees may elect national or regional applications as a useful alternative to PCT filings, as Joachim Wachenfeld and Oswin Ridderbusch explain. 2 April 2015
Biotechnology
Some of the parties involved in the landmark patent case Biogen v Medeva met in London in February to discuss the dispute in front of an invited audience. Here is an overview of their memories and the lessons they learned. 25 March 2015
Big Pharma
Orphan medicinal products in Europe benefit from a range of incentives, but the greatest of these is the promise of receiving a ten-year period of true market exclusivity, says Trevor Cook of Wilmer Cutler Pickering Hale and Dorr. 20 March 2015
Americas
In the battle for marketing approval of a biosimilar version of Neupogen under the BPCIA, applicant Sandoz stymied Amgen’s chance to join the so-called patent dance. Andrew Williams of McDonnell Boehnen Hulbert & Berghoff ponders the implications. 12 March 2015
Asia
As India appears to forge closer trade relations with the US, will the country introduce a data exclusivity legal provision and what impact would this have? LSIPR investigates. 5 March 2015
Asia
The battle between pharmaceutical and generics companies in India is once again in the spotlight, with a decision pending on another compulsory licence. The players this time are Novartis and Cipla, with the former already having drawn first blood. LSIPR investigates. 3 March 2015
Europe
Previously for LSIPR, Jane Wainwright of Potter Clarkson investigated the emergence of self-colliding patent filings in Europe and their relevance to the life sciences. As the European Patent Office begins to review this issue at the highest level, she revisits the concept and why it is now being reconsidered. 3 March 2015
Americas
The FDA could approve the US’s first biosimilar product any day now. But is the country ready for the wave of biosimilar applications that
will surely follow, and how quickly can these cut-price drugs come to market? LSIPR reports. 3 March 2015
article
In 2014, LSIPR featured some of world’s top-selling drugs that were due to lose patent exclusivity that year. The list included the big hitters Copaxone, Nexium and Cymbalta, with Evista, Micardis, Restasis and Nasonex also included. This year we have profiled five drugs set to lose US patent protection in 2015. 3 March 2015